Merck in the United States met both primary and secondary endpoints in a Phase 2b trial of the anti-TL1A antibody tulisoquibart in patients with moderate to severe hidradenitis suppurativa. At Week 16, 72% of patients in the high-dose group achieved Hidradenitis Suppurativa Clini
11 days ago
The U.S. Food and Drug Administration (FDA) has approved AbbVie’s Parkinson’s disease treatment Juvmo. AbbVie acquired the drug in 2023 when it bought Cerevel Therapeutics for about $9 billion. Juvmo is the first drug in its class to precisely target two types of dopamine recepto
11 days ago
U.S.-based Connect Biopharma said rademikibart reduced the rate of moderate or severe COPD exacerbations by 85% in a phase 2 study involving 159 patients with COPD exacerbations. Patients in the rademikibart group had no hospital or emergency department visits over 4 weeks. The c
11 days ago
U.K.-based GlaxoSmithKline (GSK) will pay U.S.-based Wave Life Sciences $12 million upfront (about 16.1 billion won). Wave Life Sciences will transfer ownership of a small interfering RNA (siRNA) candidate targeting liver disease to GSK. Wave Life Sciences will receive up to $375
11 days ago
Spain’s Highlight Therapeutics confirmed the efficacy of BO-112 in a Phase 2b trial involving patients with locally advanced, high-risk basal cell carcinoma of the head and neck. The study evaluated visual and pathological responses at week 24 after intralesional injection in 46
11 days ago
Shaperon received the clinical study report (CSR) for its Phase 2 trial of HY209 gel in patients with mild to moderate atopic dermatitis. The treatment group did not achieve statistical significance versus the placebo group on the primary endpoint, the percentage change in Eczema
11 days ago
Ildong Pharmaceutical will acquire 7,097,016 redeemable convertible preferred shares in its affiliate Idience for 36.755 billion won. Ildong Pharmaceutical decided to make the investment to strengthen strategic ties among its new drug pipeline assets. After the acquisition, Ildon
12 days ago
Denmark’s Zealand Pharma released primary endpoint data from a Phase 2 trial of petrelintide, an amylin analog it is co-developing with Roche. At week 28, the mean weight loss was highest in the 5-mg dose group, at 9.8%. Roche will begin three Phase 3 trials in patients with obes
12 days ago
Amgen said its antibody drug daksdilimab reduced disease severity in a Phase 2 trial involving 72 patients with discoid lupus. The low-dose group had a 6-point reduction in skin lupus severity scores compared with the placebo group. Amgen is moving the antibody into the registrat
12 days ago
Swiss company Galderma announced results from a 3-year long-term extension study of Nemluvio (nemolizumab) in patients with moderate to severe atopic dermatitis. At week 152, up to 75% of patients achieved at least a 90% improvement in eczema severity (EASI-90). Galderma said Nem
12 days ago
